An interventional study of Pediatric toothbrush and Sponge stick in Ventilator Associated Pneumonia ( VAP), sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Marmara University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey — 4 open to participants now, 4 under way, none of them phase 3. Pneumonia, Ventilator-Associated · Turkey.
Among the 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, and was the 19th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →4 of the 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey are open now. Recruiting first, the newest first:
National University of Singapore · Sites in Turkey, India, Malaysia and 4 more countries
Ages 18+
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–90
Aydin Adnan Menderes University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 72 is below the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 138 across the 13 interventional studies, 80 across the 7 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Marmara University is the lead sponsor of 601 studies on the registry; 137 are open to participants now.
Marmara University has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumonia, Ventilator-Associated with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07283380Marmara UniversityEffect of Two Oral Care Methods on Oral Flora and VAP in Mechanically Ventilated Patients | 2027-03-31 |
| NCT05979545National University of SingaporeEaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Pneumonia, Ventilator-Associated with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-centre, parallel-group, randomised controlled trial aims to compare the effects of two oral care methods on oral microbial colonisation and ventilator-associated pneumonia (VAP) in mechanically ventilated adult intensive care unit patients. The study is being conducted in the Anaesthesia and General Intensive Care Unit of a hospital in Türkiye, with data collection planned from October 2025 to March 2027.
A total of 46 patients are planned to be enrolled and randomly allocated in a 1:1 ratio to receive oral care using either a paediatric toothbrush or a foam swab. Oral care is provided for five consecutive days. In both groups, 0.12% chlorhexidine is used twice daily, while normal saline is used for additional oral care. Oral care frequency is determined by daily assessments using the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP).
Oropharyngeal swab samples are collected on days 1 and 6 to assess changes in microbial colonisation through the presence or absence of growth of bacterial pathogens and Candida species. VAP development is evaluated through clinical assessment supported by the Clinical Pulmonary Infection Score (CPIS). Assessors evaluating microbiological outcomes and VAP development are blinded to group allocation.
The primary outcomes are changes in oral microbial colonisation and the development of VAP. The secondary outcome is oral care frequency. The study is expected to provide evidence on the comparative effects of the two oral care methods in mechanically ventilated intensive care patients.
This study is a single-centre, parallel-group, randomised controlled trial designed to compare the effects of two oral care methods on oral microbial colonisation and the development of ventilator-associated pneumonia (VAP) in mechanically ventilated adult intensive care unit (ICU) patients. The two methods are oral care performed using a paediatric toothbrush and oral care performed using a foam swab.
The study is being conducted in the Anaesthesia and General Intensive Care Unit of a hospital in Türkiye, with data collection planned from October 2025 to March 2027. A total of 46 eligible patients are planned to be enrolled and randomly allocated in a 1:1 ratio to the paediatric toothbrush group or the foam swab group.
Oral care is provided for five consecutive days. In both groups, 0.12% chlorhexidine is used twice daily, while normal saline is used for additional oral care. The frequency of oral care is determined by daily assessments using the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP), developed by the researchers. The scale assesses oral and clinical conditions to guide individualised oral care frequency.
Oropharyngeal swab samples are collected on days 1 and 6 to evaluate changes in microbial colonisation. Microbiological assessments include the presence or absence of growth of bacterial pathogens, including Staphylococcus spp., Pseudomonas spp. and Acinetobacter spp., as well as Candida species. Findings are documented using the Microbiology Patient Follow-up Form.
The development of VAP is evaluated through clinical assessment supported by the Clinical Pulmonary Infection Score (CPIS). The CPIS incorporates body temperature, leukocyte count, tracheal secretions, oxygenation, chest radiographic findings and microbiological results. CPIS assessments are performed at baseline and on day 6, and findings are recorded using the Clinical Pulmonary Infection Score Patient Follow-up Form.
Assessors evaluating microbiological outcomes and VAP development are blinded to group allocation. The primary outcomes are changes in oral microbial colonisation and the development of VAP. The secondary outcome is oral care frequency determined using the OCAS-ICP.
The study is expected to provide evidence on the comparative effects of oral care using a paediatric toothbrush versus a foam swab on oral microbial colonisation and VAP development in mechanically ventilated ICU patients.
The criteria were revised on the registry on Nov 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive oral care with a pediatric toothbrush for 5 days. Oral swabs and CPIS scores will be monitored.
Device: Pediatric toothbrush
Patients will receive oral care with a sponge stick for 5 days. Oral swabs and CPIS scores will be monitored.
Device: Sponge stick
Oral care will be using a pediatric toothbrush for 5 days; oral swabs and CPIS scores will be monitored.
Oral care will be using a sponge stick for 5 days; oral swabs and CPIS scores will be monitored.
Changes in Oral Microbial Colonisation
Oropharyngeal swab samples are collected on Days 1 and 6 to assess the presence or absence of growth of bacterial pathogens associated with ventilator-associated pneumonia and Candida species. Changes in oral microbial colonisation are evaluated by comparing the culture results for each microorganism between Days 1 and 6.
Time frame: Day 1 and Day 6
Incidence of Ventilator-Associated Pneumonia (VAP)
The development of ventilator-associated pneumonia (VAP) is determined through clinical assessment by the treating physician, supported by the Clinical Pulmonary Infection Score (CPIS). The CPIS includes six parameters: body temperature, leukocyte count, tracheal secretions, oxygenation (PaO₂/FiO₂), chest radiographic findings, and microbiological culture results. The total score ranges from 0 to 12, with higher scores indicating a greater likelihood of pulmonary infection. VAP incidence is recorded as present or absent.
Time frame: Day 1 and Day 6
Oral care frequency assessed by the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP)
Oral care frequency and oral health status will be assessed using the Oral Care Assessment Scale for Intensive Care Patients (OCAS-ICP). The scale consists of 10 assessment parameters and 17 factors corresponding to these parameters. Each category is scored from 0 to 4 depending on the presence of relevant factors. The total score obtained from the scale ranges from 0 to 26, with higher scores indicating poorer oral health status and a greater presence of risk factors, and lower scores indicating better oral health status. Patients will be evaluated daily during their intensive care unit stay. Based on the total OCAS-ICP score, oral care will be planned and implemented as follows: patients with a total score of 0-8 points will receive oral care twice daily (2×1), those with 9-17 points will receive oral care four times daily (4×1), and those with 18-26 points will receive oral care six times daily (6×1).Patients will be evaluated daily from Day 1 to Day 6.
Time frame: Day 1 to Day 5
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There is currently no plan to share individual participant data (IPD) with other researchers. This decision takes into account ethical considerations and the importance of protecting patient confidentiality in a critically ill population.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.
Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 17 months is below that.
Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Mar 2027 and completion Oct 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →